Home › Therapeutic areas › GI/Hepatology
GI/Hepatology (17 companies · 11 conditions)
Conditions
Eosinophilic Esophagitis 4 Rare Celiac Disease 3 Inflammatory Bowel Disease 3 Gastroparesis 2 Wilson's Disease 2 Rare Alcohol-Associated Liver Disease 1 Chronic Idiopathic Constipation 1 Irritable Bowel Syndrome with Constipation 1 Nausea and Vomiting 1 Primary Sclerosing Cholangitis 1 Rare Short Bowel Syndrome 1 Rare
Companies
| Ticker | Company | Therapeutic areas | In GI/Hepatology | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ABSI | Absci | DermatologyGI/Hepatology+1 | 1 | Phase 1 | $1.31B | 6 |
| ACRS | Aclaris Therapeutics | DermatologyGI/Hepatology+1 Rare | 1 | Phase 2 | $536M | 7 |
| ACRV | Acrivon Therapeutics | GI/HepatologyOncology Rare | 1 | Phase 2 | $61.4M | 9 |
| ALT | Altimmune | GI/HepatologyMetabolic+1 | 1 | Phase 3 | $298M | 3 |
| ANAB | AnaptysBio | DermatologyGI/Hepatology+2 Rare | 2 | Approved | $1.36B | 9 |
| APGE | Apogee Therapeutics | DermatologyGI/Hepatology+1 Rare | 1 | Phase 2 | — | 9 |
| ARDX | Ardelyx | GI/HepatologyRenal | 2 | Approved | $799M | 4 |
| CMMB | Chemomab Therapeutics | GI/HepatologyImmunology+1 Rare | 1 | Phase 2 | $13.2M | 4 |
| IRON | Disc Medicine | GI/HepatologyHematology+2 Rare | 1 | Phase 3 | $3.49B | 9 |
| ENTX | Entera Bio | GI/HepatologyMetabolic Rare | 1 | Phase 2 | $522M | 4 |
| ETON | Eton Pharmaceuticals | GI/HepatologyInfectious Disease+3 Rare | 2 | Approved | $1.84B | 17 |
| FBRX | Forte Biosciences | DermatologyGI/Hepatology | 1 | Phase 2 | — | 3 |
| IMUX | Immunic | GI/HepatologyNeurology | 1 | Phase 3 | $116M | 4 |
| MESO | Mesoblast | CardiovascularGI/Hepatology+2 Rare | 1 | Approved | $1.54B | 5 |
| PRME | Prime Medicine | GI/HepatologyRespiratory Rare | 1 | Phase 1 | $699M | 3 |
| PCSA | Processa Pharmaceuticals | GI/HepatologyImmunology+2 Rare | 1 | Phase 2 | $4.8M | 7 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 2 | Approved | $230M | 27 |
No companies match.